Aclidinium bromide/formoterol fumarate vs Glycopyrrolate/formoterol fumarate

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Obstructive Pulmonary Disease

Shared mechanisms: Muscarinic acetylcholine receptor (M3) · Beta-2 adrenergic receptor · full Chronic Obstructive Pulmonary Disease pipeline

Aclidinium bromide/formoterol fumarate · Duaklir Pressair

Rights held by Azurity Pharmaceuticals and partners; US product discontinued

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule combination
Partial signal

NCT01437397 · Phase 3 · completed

This was a large randomized, quadruple-blind, placebo- and active-controlled trial with 1,692 randomized participants, using the regulator-accepted clinical lung-function measure FEV1 as its primary endpoint. Results were mixed: the 400/12 μg combination significantly improved post-dose FEV1 versus aclidinium and trough FEV1 versus formoterol, whereas the 400/6 μg combination did not significantly improve trough FEV1 versus formoterol (p=0.133).

Reported efficacy

Change From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1) (Week 24, 1-hour morning post-dose); Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide/Formoterol Fumarate (Week 24, morning pre-dose (trough)); Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide (Week 24, morning pre-dose (trough)): Change From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1) (Week 24, 1-hour morning post-dose): AB/FF 400/12 μg 0.248 Litres (Standard Error 0.013) vs AB 400 μg 0.156 Litres (Standard Error 0.013) | FF 12 μg 0.138 Litres (Standard Error 0.013) | Placebo -0.05 Litres (Standard Error 0.013) (met)

Result source: NCT03022097

Glycopyrrolate/formoterol fumarate · Bevespi Aerosphere

Marketed by AstraZeneca

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule combination
Weak signal

NCT03324607 · Phase 2/3 · completed

The study used a single treatment group without randomization, blinding, or a placebo or active comparator, and only 17 participants contributed to the primary imaging analysis. Its primary endpoints were surrogate MRI measures rather than established clinical outcomes, and the findings were mixed across those measures, so they provide limited evidence about Bevespi’s clinical effectiveness.

Reported efficacy

Ventilation Distribution as Measured by Ventilation Defect+Low Percent (Week 2); Barrier Uptake. (2 weeks); Red Blood Cell (RBC) Uptake (2 weeks): Ventilation Distribution as Measured by Ventilation Defect+Low Percent (Week 2): Treatment — Baseline: 57.8 percentage of total ventilation (Standard Deviation 8.4); Week 2: 52.5 percentage of total ventilation (Standard Deviation 10.6) (mixed)

Result source: NCT03324607

Results for Chronic Obstructive Pulmonary Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAclidinium bromide/​formoterol fumarateGlycopyrrolate/​formoterol fumarate
Moderate or severe exacerbations, annualised rate—Not reported—Not reported
Trough FEV1, change0.1 vs -0.0+0.1 vs placebo400/12 μg · wk 24 · n 335NCT01437397
5 other results
  • 0.1 vs -0.0 400/6 μg · wk 24 · n 333 · Phase 3 · primary NCT01437397
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 349 · Phase 3 · primary NCT01462942
  • 0.1 vs -0.1 400/6 μg · wk 24 · n 340 · Phase 3 · primary NCT01462942
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 262 · Phase 3 · primary NCT03022097
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 262 · Phase 3 · primary NCT03022097
—Not reported
SGRQ total, change-6.6 vs -2.2−4.4 vs placebo400/12 μg · wk 24 · n 335NCT01437397
4 other results
  • -5.9 vs -2.2 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01437397
  • -7.2 vs -6.5 400/12 μg · wk 24 · n 338 · Phase 3 · secondary NCT01462942
  • -8.3 vs -6.5 400/6 μg · wk 24 · n 332 · Phase 3 · secondary NCT01462942
  • -8.7 vs -4.7 400/12 μg · wk 24 · n 262 · Phase 3 · secondary NCT03022097
—Not reported
TDI focal score2.0 vs 0.6+1.4 vs placebo400/12 μg · wk 24 · n 335NCT01437397
5 other results
  • 2.0 vs 0.6 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01437397
  • 2.5 vs 1.2 400/12 μg · wk 24 · n 344 · Phase 3 · secondary NCT01462942
  • 2.4 vs 1.2 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01462942
  • 2.9 vs 2.1 400/12 μg · wk 24 · n 262 · Phase 3 · secondary NCT03022097
  • 1.9 vs 1.9 wk 24 · n 353 · Phase 3 · secondary NCT01908140
—Not reported

Moderate or severe exacerbations, annualised rate

Aclidinium bromide/​formoterol fumarate
—Not reported
Glycopyrrolate/​formoterol fumarate
—Not reported

Trough FEV1, change

Aclidinium bromide/​formoterol fumarate
0.1 vs -0.0+0.1 vs placebo400/12 μg · wk 24 · n 335NCT01437397
5 other results
  • 0.1 vs -0.0 400/6 μg · wk 24 · n 333 · Phase 3 · primary NCT01437397
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 349 · Phase 3 · primary NCT01462942
  • 0.1 vs -0.1 400/6 μg · wk 24 · n 340 · Phase 3 · primary NCT01462942
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 262 · Phase 3 · primary NCT03022097
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 262 · Phase 3 · primary NCT03022097
Glycopyrrolate/​formoterol fumarate
—Not reported

SGRQ total, change

Aclidinium bromide/​formoterol fumarate
-6.6 vs -2.2−4.4 vs placebo400/12 μg · wk 24 · n 335NCT01437397
4 other results
  • -5.9 vs -2.2 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01437397
  • -7.2 vs -6.5 400/12 μg · wk 24 · n 338 · Phase 3 · secondary NCT01462942
  • -8.3 vs -6.5 400/6 μg · wk 24 · n 332 · Phase 3 · secondary NCT01462942
  • -8.7 vs -4.7 400/12 μg · wk 24 · n 262 · Phase 3 · secondary NCT03022097
Glycopyrrolate/​formoterol fumarate
—Not reported

TDI focal score

Aclidinium bromide/​formoterol fumarate
2.0 vs 0.6+1.4 vs placebo400/12 μg · wk 24 · n 335NCT01437397
5 other results
  • 2.0 vs 0.6 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01437397
  • 2.5 vs 1.2 400/12 μg · wk 24 · n 344 · Phase 3 · secondary NCT01462942
  • 2.4 vs 1.2 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01462942
  • 2.9 vs 2.1 400/12 μg · wk 24 · n 262 · Phase 3 · secondary NCT03022097
  • 1.9 vs 1.9 wk 24 · n 353 · Phase 3 · secondary NCT01908140
Glycopyrrolate/​formoterol fumarate
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Aclidinium bromide/formoterol fumarate: 4 of 4 rows · Glycopyrrolate/formoterol fumarate: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAclidinium bromide/​formoterol fumarateGlycopyrrolate/​formoterol fumarate
Dropout rate
19.5%400/12 μga
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 7 more results
18.3%400/6 μg
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
7.9%400/12 μg
NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3
14.1%
NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
8.8%400/12 μg
NCT01462942 · Phase 3
10.5%400/6 μg
NCT01462942 · Phase 3
32.4%400 μg/12 μg
NCT01437540 · Phase 3 · registry result, not featured evidence
5%400/12 BID
NCT03276078 · Phase 2 · registry result, not featured evidence
0%b
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3
show 1 more result
—
NCT03081156 · Phase 4 · registry result, not featured evidence
Discontinued due to AEs
6.2%400/12 μga
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 7 more results
6.5%400/6 μg
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
1.1%400/12 μg
NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3
4.7%
NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
3.1%400/12 μg
NCT01462942 · Phase 3
2.6%400/6 μg
NCT01462942 · Phase 3
6.6%400 μg/12 μg
NCT01437540 · Phase 3 · registry result, not featured evidence
5%400/12 BID
NCT03276078 · Phase 2 · registry result, not featured evidence
—b
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3
show 1 more result
—
NCT03081156 · Phase 4 · registry result, not featured evidence
Serious AEs
5.7%400/12 μga
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 7 more results
5.4%400/6 μg
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
7.2%400/12 μg
NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3
7.5%
NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
6%400/12 μg
NCT01462942 · Phase 3
4.7%400/6 μg
NCT01462942 · Phase 3
9.7%400 μg/12 μg
NCT01437540 · Phase 3 · registry result, not featured evidence
5%400/12 BID
NCT03276078 · Phase 2 · registry result, not featured evidence
0%b
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3
show 1 more result
12.5%
NCT03081156 · Phase 4 · registry result, not featured evidence
Most frequent reported AEs
400/12 μga
chronic obstructive pulmonary disease 15.2% (placebo 17.5%)
cough 5.1% (placebo 3.6%)
nasopharyngitis 4.8% (placebo 3.6%)
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 7 more results
400/6 μg
chronic obstructive pulmonary disease 14.7% (placebo 17.5%)
nasopharyngitis 5.1% (placebo 3.6%)
cough 3.9% (placebo 3.6%)
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
400/12 μg
upper respiratory tract infection 11.8% (placebo 8.9%)
chronic obstructive pulmonary disease 9.5% (placebo 13%)
NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3
chronic obstructive pulmonary disease 15%
headache 6%
nasopharyngitis 5.6%
NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
400/12 μg
chronic obstructive pulmonary disease 8.6% (placebo 11.9%)
nasopharyngitis 7.8% (placebo 7.2%)
headache 7.5% (placebo 8.2%)
NCT01462942 · Phase 3
400/6 μg
chronic obstructive pulmonary disease 9.4% (placebo 11.9%)
nasopharyngitis 7.9% (placebo 7.2%)
headache 7.1% (placebo 8.2%)
NCT01462942 · Phase 3
400 μg/12 μg
chronic obstructive pulmonary disease 27%
urinary tract infection 6.6%
nasopharyngitis 6.4%
NCT01437540 · Phase 3 · registry result, not featured evidence
400/12 BID
protein urine present 15%
NCT03276078 · Phase 2 · registry result, not featured evidence
—

Notes

  1. aPopulation comparability has not been reviewed for 4 of these studies.
  2. bPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Aclidinium bromide/formoterol fumarate

FEV1 Change 1h 0.247 vs -0.037 placebo L @ 24wk400/12 μg
absolute change · L
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 4 more results
0.226 vs -0.037 placebo L @ 24wk400/6 μg
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
0.269 vs -0.03 placebo L @ 24wk400/12 μg
NCT01462942 · Phase 3
0.213 vs -0.03 placebo L @ 24wk400/6 μg
NCT01462942 · Phase 3
0.248 vs -0.05 placebo L @ 24wk400/12 μg
NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3
FEV1 Trough 0.095 vs -0.035 placebo L @ 24wk400/12 μg
absolute change · L
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 5 more results
0.076 vs -0.035 placebo L @ 24wk400/6 μg
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
0.083 vs -0.061 placebo L @ 24wk400/12 μg
NCT01462942 · Phase 3
0.05 vs -0.061 placebo L @ 24wk400/6 μg
NCT01462942 · Phase 3
0.081 vs -0.084 placebo L @ 24wk400/12 μg
NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3
0.081 vs -0.084 placebo L @ 24wk400/12 μg
NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3
TDI Focal 2.017 vs 0.582 placebo score @ 24wk400/12 μg
absolute change · score
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 5 more results
1.977 vs 0.582 placebo score @ 24wk400/6 μg
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
2.508 vs 1.215 placebo score @ 24wk400/12 μg
NCT01462942 · Phase 3
2.377 vs 1.215 placebo score @ 24wk400/6 μg
NCT01462942 · Phase 3
2.9 vs 2.1 placebo score @ 24wk400/12 μg
NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3
1.9 vs 1.9 Salmeterol / Fluticasone score @ 24wk
NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
SGRQ Total -6.568 vs -2.215 placebo score @ 24wk400/12 μg
absolute change · score
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 4 more results
-5.942 vs -2.215 placebo score @ 24wk400/6 μg
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
-7.164 vs -6.511 placebo score @ 24wk400/12 μg
NCT01462942 · Phase 3
-8.339 vs -6.511 placebo score @ 24wk400/6 μg
NCT01462942 · Phase 3
-8.7 vs -4.7 placebo score @ 24wk400/12 μg
NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3
FEV1 Peak 0.324 vs 0.008 placebo L @ 24wk400/12 μg
absolute change · L
NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3
show 1 more result
1.655 vs 1.562 Salmeterol / Fluticasone L @ 24wk
NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3

Glycopyrrolate/formoterol fumarate

FVC 0.342 L @ 2wk
absolute change · L
No placebo or comparator arm
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3 · converted to L from 342 mL as posted
FEV1 0.219 L @ 2wk
absolute change · L
No placebo or comparator arm
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3 · converted to L from 219 mL as posted
Six Minute Walk 16.2 m @ 2wk
absolute change · m
No placebo or comparator arm
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3
SGRQ Total -1.2 score @ 2wk
absolute change · score
No placebo or comparator arm
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3
RPD -0.75 score @ 2wk
absolute change · score
No placebo or comparator arm
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3
Exercise Endurance Time Seconds 382.5 vs 328 placebo seconds
absolute value · seconds
NCT03081156 · Phase 4 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aclidinium bromide/formoterol fumarate's landscape · Glycopyrrolate/formoterol fumarate's landscape